Introduction: Cutaneous squamous cell carcinoma (cSCC) occurs times more in organ transplant recipients than in the general population. T cells, which are targeted by immunosuppressive drugs, are involved in anti-tumour immune surveillance and their function is regulated by DNA methylation. We aim to discover differentially methylated regions (DMRs) in T cells involved in de novo cSCC development after kidney transplantation. Genome-wide DNA methylation of T cells was studied at time of transplantation (pre-Tx cohort) and prior to the clinical presentation of the first cSCC after kidney transplantation (post-Tx cohort).
Methods: Kidney transplant recipients with a future post-transplant cSCC (post-Tx n=19; pre-Tx n=27) were matched to recipients without cSCC (post-Tx n=19; pre-Tx n=27). Pure T cells were isolated by cell sorting from PMBCs and genome-wide DNA methylation was measured using Illumina's Infinium 450K arrays. Linear mixed modelling was applied to adjust for confounders followed by comb-p to find DMRs. Pyrosequencing was used as a technical validation of the array results.
Results: Post-transplantation 7 DMRs were found between recipients with a future cSCC and those without cSCC. The top results include an intragenic region of SERPINB9, which was located in an actively transcribed gene in T cells, and a known tumour suppressor microRNA VTRNA2-1. Prior to transplantation 16 DMRs were found. Twelve of these 16 DMRs were located in genomic regions that are actively transcribed or enhancer regions. That includes the DMR annotated to FLOT1, a protein involved in T-cell migration.
Methylation values obtained with the array were successfully validated with pyrosequencing.
Conclusion: Our results demonstrate that the T cells of kidney transplant recipients with a future post-transplant cSCC have different DNA methylation profiles compared to the T cells of kidney transplant recipients without cSCC, before the clinical presentation of a de novo cSCC and also before transplantation. (1) to show the capacity of cTfh to differentiate B cells into plasma cells and produce antibodies, (2) to study cTfh in chronic kidney disease patients pretransplantation, (3) to follow up variations in cTfh posttransplantation and (4) to correlate differences in cTfh distribution with graft outcome.
Methods:
We isolated peripheral blood mononuclear cells at pretransplantation and at 7 and 14 days and 1, 3, 6 and 12 months posttransplantation from a prospective cohort of renal transplantation recipients (n=163). We analyzed cTfh by flow cytometry as CD4+CXCR5+ or CD4 +CXCR5+CCR7lowPD1high. cTfh were cocultured with B cells to interrogate their capacity to stimulate conversion to plasmablasts and antibody production. Clinical and immunological data were prospectively collected.
Results: First, we showed that when co-cultured with cTfh, B cells differentiated into plasmablasts and produce IgG.Pretransplantation, cTfh were decreased in patients who had received dialysis compared to those directly transplanted (p<0.01). Conversely, cTfh were increased in retransplanted patients, in those with previous blood transfusions and in patients with anti-HLA antibodies pretransplantation (sensitized patients) (p<0.05, all comparisons). During follow-up, cTfh decreased a week after transplantation in patients who received thymoglobulin as induction therapy (p<0.05) and started to increase three months after transplantation. Patients who received thymoglobulin tripled their cTfh six months posttransplantation. Basiliximab treatment did not
